ISA Pharmaceuticals
Developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
€26.0m | Series B | ||
| Total Funding | 000k | ||
Related Content
ISA Pharmaceuticals focuses on developing targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections. The company operates in the biotechnology sector, primarily serving patients and healthcare providers. ISA Pharmaceuticals' business model revolves around the research, development, and commercialization of immunotherapy treatments. Revenue is generated through the sale of these treatments, as well as potential partnerships and licensing agreements with other pharmaceutical companies. The company is actively involved in clinical trials, such as the Phase II combination trial of its lead immunotherapy ISA101b. ISA Pharmaceuticals also adapts to emerging health crises, as evidenced by its development of ISA106 SLP therapeutic for COVID-19.
Keywords: immunotherapeutics, cancer treatment, virus infections, biotechnology, clinical trials, ISA101b, ISA106, COVID-19, healthcare, rational design.